Conference call scheduled for 9am
ET
REHOVOT, Israel, Feb. 27,
2023 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN)
(TASE: EVGN), a leading computational biology company aiming to
revolutionize life-science product development announced today that
it will release its financial results for the fourth quarter and
full year 2022 on Thursday, March 9,
2023.
Later that day, Company management will host a conference call
to discuss the results at 9:00AM Eastern
time, 4:00 PM Israel time.
To access the conference call, please dial +1-888-281-1167 toll
free from the United States, or
+972-3-918-0609 internationally. Access to the call will also be
available via live webcast through the Company's website at
www.evogene.com.
A replay of the conference call will be available approximately
two hours following the completion of the call. To access the
replay, please dial +1-888-326-9310 toll free from the United States, or +972-3-925-5901
internationally. The telephone replay will be accessible for three
days, but an archive of the webcast will be available on the
webcast link for the following twelve months.
About Evogene Ltd.:
Evogene (NASDAQ: EVGN) (TASE: EVGN) is a computational biology
company aiming to revolutionize the development of life-science
based products by utilizing cutting edge technologies to increase
probability of success while reducing development time and cost.
Evogene established three unique technological engines –
MicroBoost AI, ChemPass AI and GeneRator AI –
leveraging Big Data and Artificial Intelligence and incorporating
deep multidisciplinary understanding in life sciences. Each
technological engine is focused on the discovery and
development of products based on one of the following core
components: microbes (MicroBoost AI), small molecules (ChemPass
AI), and genetic elements (GeneRator AI). Evogene uses its
technological engines to develop products through subsidiaries and
with strategic partners. Currently, Evogene's main
subsidiaries utilize the technological engines to develop novel
products as follows: human microbiome-based therapeutics by Biomica
Ltd., medical cannabis products by Canonic Ltd., ag-chemicals by
AgPlenus Ltd. and ag-biologicals by Lavie Bio Ltd. For more
information, please visit: www.evogene.com.
Investor Relations Contact:
Kenny Green
Investor Relations
E: kenny.green@evogene.com
T: +1 212 378 8040
Logo - https://mma.prnewswire.com/media/1947468/Evogene.jpg
View original
content:https://www.prnewswire.com/news-releases/evogene-schedules-fourth-quarter-and-full-year-2022-financial-results-release--conference-call-for-march-9-2023-301756482.html
SOURCE Evogene